Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2, Dose-finding, Cross-over Study to Evaluate the Effect of a NES/E2 Transdermal Gel Delivery on Ovulation Suppression in Normal Ovulating Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Woman is between 18 and 40 years of age~* Has intact uterus and ovaries~* Has regular menstrual cycles of 25-35 days duration~* Able to comply with the protocol, including frequent blood sampling, and lives within the catchment area of the clinic~* Understands the study procedures and agrees to participate in the study by giving written informed consent~* Able to use non-hormonal, double-barrier contraceptives (e.g. condoms and diaphragm) with every act of intercourse, or has been sterilized with tubal ligation, or only male partner has been sterilized with vasectomy~* Progesterone \>10 nmol/L in at least one sample in the lead-in cycle~Exclusion Criteria:~* All contraindications to OC use including~* Thrombophlebitis or thromboembolic disorders~* Past history of deep vein thrombophlebitis or thromboembolic disorders~* Past or current cerebrovascular or coronary artery disease~* Known or suspected carcinoma of the breast~* Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia~* Undiagnosed abnormal genital bleeding~* Cholestatic jaundice of pregnancy or jaundice with prior pill use~* Hepatic adenomas or carcinomas~* Woman has a history of headaches with focal neurological symptoms~* Known or suspected pregnancy~* Aged \>35 and smoker~* BMI \>29~* Positive urine pregnancy test at the screening or baseline visit~* Desired pregnancy within the duration of the study~* Known hypersensitivity to progestins~* Known hypersensitivity to estrogen~* Undiagnosed vaginal discharge or vaginal lesions or abnormalities~* In accordance with the Bethesda system of classification Women with a current abnormal Pap smear suggestive of high-grade pre cancerous lesion(s), including HGSIL, are excluded~* Women with LGSIL or ASCUS/high-risk HPV positive may participate if further evaluated with colposcopy and biopsy and no evidence of a lesion with a severity \>CIN I is present and/or endocervical curettage is negative~* Women with a biopsy finding of CIN I should have follow up for this finding per standard of care; women are excluded if treatment is indicated In accordance with other Pap class systems~* Women with high grade dysplasia are excluded~* Women with low grade dysplasia or CIN I interpretation on Pap smear may participate based on investigator discretion in accordance with local standard of care~* Breastfeeding~* Cancer (past history of any carcinoma or sarcoma)~* History of a significant psychiatric disorder, including severe depression.~* Chronic or acute liver or renal disease~* Hypertension-- controlled by medication or defined by diastolic BP 85 mm Hg or systolic BP 135mm Hg after 15 minutes rest~* Dermatitis, psoriasis or other severe skin disorder~* Known or suspected alcoholism or drug abuse~* Clinically significant abnormalities of laboratory safety tests~* Chronic disease or history of illness that, in the opinion of the investigator, might confound the results of the study or pose additional risk to the subject~* Woman is participating or has participated in another clinical study (involving an investigational drug) within one month prior to enrollment.~* Use of injectable contraceptives during the previous 3 months (e.g. cyclofem) or 9 months (e.g. DMPA)~* Use of oral contraceptives within the past 1 month~* Use of concomitant drugs that may interact with the study drugs

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 0.5 ml of NES/E2 equaling 0.45 g and contains 1.5 mg NES/0.5 mg E2
- 2 (Type: ACTIVE_COMPARATOR): 1.0 ml of NES/E2 gel equaling 0.9 g and contains 3.0 mg NES/1.0 mg E2
- 3 (Type: ACTIVE_COMPARATOR): 1.5 ml of NES/E2 gel equaling 4.5 mg NES/1.5 mg E2

Based on this trial design, predict the completion outcome and termination type (if applicable).